Taiwan Advanced Nanotech

Taiwan Advanced Nanotech Interest Coverage

The Interest Coverage Ratio of Taiwan Advanced Nanotech (6797.TWO) as of Nov 11, 2026 is -7.45. In the previous year, Interest Coverage Ratio was 2.98 — a change of -349.74% (lower).

Interest Coverage

-7.45

YoY

-349.74%

Last updated:

Interest Coverage Ratio of Taiwan Advanced Nanotech is 2023 -7.45 . Interest Coverage Ratio of Taiwan Advanced Nanotech was 2022 2.98 . It decreases by -349.74% lower compared to the previous year.

The Taiwan Advanced Nanotech Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2017
-6.79 TWD
Jan 1, 2018
-23.66 TWD
Jan 1, 2019
-64.35 TWD
Jan 1, 2020
31.59 TWD
Jan 1, 2021
38.93 TWD
Jan 1, 2022
2.98 TWD
Jan 1, 2023
-7.45 TWD
The Taiwan Advanced Nanotech Interest Coverage history
YEARInterest CoverageYoY
-7.45-349.74%
2.98-92.34%
38.93+23.24%
31.59-149.09%
-64.35+171.95%
-23.66+248.47%
-6.79—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Taiwan Advanced Nanotech Stock analysis

What does Taiwan Advanced Nanotech do? Taiwan Advanced Nanotech, Inc. generates revenue through the sale of nucleic acid purification products, including SLA series, Maelstrom series, and LH series instruments designed for DNA/RNA extraction. The company also sells specialized reagents such as virus nucleic acid extraction reagent 665 series, blood nucleic acid extraction reagent 611/61E series, and tissue nucleic acid extraction reagent 6T2/6K2 series. These products are marketed to customers in Taiwan, South Korea, and China, with sales primarily focused on laboratory and medical applications requiring nucleic acid processing. The company's product portfolio targets research institutions, diagnostic laboratories, and healthcare facilities seeking efficient nucleic acid extraction solutions. By offering a range of instruments and reagents tailored to specific extraction needs, Taiwan Advanced Nanotech addresses key segments in the biotechnology and medical diagnostics markets. Sales are distributed across Taiwan, South Korea, and China, reflecting the company's regional market focus. Revenue streams are derived from direct sales of instruments and reagents to end-users in the biotech and healthcare sectors. The SLA, Maelstrom, and LH series instruments serve as core revenue drivers, complemented by recurring reagent sales for ongoing laboratory operations. This dual-product approach ensures steady income from both capital equipment and consumable supplies. Taiwan Advanced Nanotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Taiwan Advanced Nanotech stock

Interest Coverage Ratio of Taiwan Advanced Nanotech is -7.45 in 2023.

Interest Coverage Ratio of Taiwan Advanced Nanotech changed from 2.98 to -7.45, representing a -349.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Taiwan Advanced Nanotech since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Taiwan Advanced Nanotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Taiwan Advanced Nanotech

All Key Metrics — Taiwan Advanced Nanotech